Healthy Volunteers
Conditions
Keywords
Drug therapy
Brief summary
The purpose of this study is to evaluate the oral bioavailability of two new tablet formulations of TAK-385 (T4 Formulation B and T4 Formulation C) under fasted and fed conditions, relative the T2 Formulation tablet; and to estimate the effect of food on the pharmacokinetics (PK) of a single oral dose of the T4 Formulation B tablet and the T4 Formulation C tablet.
Detailed description
The drug being tested in this study is called TAK-385. In this study, two new formulations of TAK-385 are being evaluated under fasted and fed conditions, relative to a previous formulation of TAK-385, to assess its bioavailability and how it is processed by the body. This study will look at lab results of people who take TAK-385. The study will enroll approximately 54 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups (Arms). Participants in Arm 1 will receive TAK-385 T2 Formulation 120 mg tablet (80mg + 40mg tablets) under fasted conditions, TAK-385 T4 Formulation B 120 mg tablet under fasted conditions, and TAK-385 T4 Formulation B 120 mg tablet under fed conditions. Participants in Arm 2 will receive TAK-385 T2 Formulation 120 mg tablet (80mg + 40mg tablets) under fasted conditions, TAK-385 T4 Formulation C 120 mg tablet under fasted conditions, and TAK-385 T4 Formulation C 120 mg tablet under fed conditions. Participants in each arm will be randomized to receive study drug in one of 6 treatment sequences. Study medication will be administered as a single dose on Days 1, 11 and 21. There will be a 10-day washout period between each dose. This single-centre trial will be conducted in the United States. The overall time to participate in this study is 51 days. Participants will make 10 visits to the clinic, including three 4-day periods of confinement to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.
Interventions
DRUGTAK-385 T2 Formulation
TAK-385 T2 Formulation tablets
DRUGTAK-385 T4 Formulation B
TAK-385 T4 Formulation B tablets
DRUGTAK-385 T4 Formulation C
TAK-385 T4 Formulation C tablets
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 18 to 55 years, inclusive, at the time of consent. 2. Healthy adult male, as determined by a physician evaluation that includes: * Medical history (ie, no clinically significant medical conditions requiring ongoing drug therapy). * Physical examination. * Vital signs. * Electrocardiogram (ECG). * Laboratory evaluation (hematology, biochemistry, and urinalysis). * No acute illness within 30 days before screening that required prescription or over-the-counter (OTC) medicines. 3. Weight ≥ 55 kg and body mass index (BMI) between 18.0 and 32.0 kg/m\^2 inclusive, at Screening. 4. Nonsmoker for at least 2 years and does not use nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, or nicotine patch or gum). 5. Male participants, even if surgically sterilized (ie, status postvasectomy), who: * Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods for the female partner\] and withdrawal are not acceptable methods of contraception.) 6. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care. 7. Suitable venous access for the study-required blood sampling. 8. Abstains from behavior that increases susceptibility to contract blood-borne pathogens (eg, obtaining a tattoo or participating in unsafe needle use for any purpose) during the 28 days before study entry. 9. In the opinion of the investigator, the participant or legal guardian is capable of understanding and complying with protocol requirements.
Exclusion criteria
1. Has any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. 2. Has received any investigational compound within 30 days (or 5 half- lives of the compound, if longer) before check-in (Day -1). 3. Has received TAK-385 in a previous clinical study. 4. Has current or recent (within 6 months) history of gastrointestinal disease that would be expected to influence the absorption of drugs (ie, history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent heartburn, or any surgical intervention). 5. Is lactose intolerant. 6. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within 1 year before screening or is unwilling to agree to abstain from alcohol and drugs throughout the study. 7. Has a positive test result for hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody at Screening. 8. Has a positive urine drug result for drugs of abuse or alcohol at Screening or check-in (Day -1). 9. Has taken any prescription medicine or herbal preparations (eg, St. John's wort) or received any immunizations within 30 days before check-in (Day -1). 10. Has taken any OTC medications or vitamin supplements within 14 days before check-in (Day -1). Excluded from this list is occasional use of acetaminophen (paracetamol) ≤ 1 g/day or other medication approved by the sponsor on a case-by-case basis. 11. Is unwilling to agree to abstain from caffeine and food products from 72 hours before check-in (Day -1) to completion of the study. 12. Has a clinically significant electrocardiogram (ECG) abnormality at Screening or check-in (Day -1) or a QTc interval (by the Fridericia correction) of 450 msec or greater. The participant has a history of cardiac disease including, but not limited to, congenital long-QT syndrome, torsades de pointes or torsades de pointes risk factors (eg, cardiac insufficiency, hypokalemia, family history of long-QT syndrome, current use of Class IA \[eg, quinidine or procainamide\] or Class III \[eg, amiodarone or sotalol\] antiarrhythmic medications or other medications with known effects on QT interval). 13. Has abnormal laboratory values suggesting a clinically significant disease at Screening or check-in (Day -1) or has abnormalities in the following laboratory parameters: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) value \>1.5 times the upper limit of normal. 14. Has engaged in heavy exercise (marathon running, weight lifting, etc) within 72 hours before check-in (Day -1) or is unwilling to agree to abstain from heavy exercise throughout the study. 15. Has known allergy to TAK-385 or its excipients. 16. Participants who, for any reason, are deemed by the investigator to be inappropriate for this study, including participants who are unable to communicate or to cooperate with the investigator. 17. Any participant who is an immediate family member, investigational site employee, or in a dependent relationship with an investigational site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-385 | Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose |
| AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385 | Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose |
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385 | Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | From Day 1 to 30 days after the last dose of study drug (Up to 51 days total) | An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. |
| Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Baseline and Days 4, 10, 14, 20, 24 and 26 | Participants with shifts from normal at Baseline in safety laboratory values (Clinical Chemistry, Hematology and Urinalysis) collected throughout study. Low=below normal reference range, Normal=within reference range, High=above normal reference range and Abnormal=outside of normal reference range. |
| Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant | Days 1, 11, 21 and 26 | A 12-lead ECG was administered. The investigator interpreted the ECG using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant. |
| Percentage of Participants With Markedly Abnormal Vital Sign Measurements | From Day 1 to Day 26 | The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study. |
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 | Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose | — |
| Terminal Phase Elimination Half-Life (T1/2) for TAK-385 | Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose | — |
| Oral Clearance (CL/F) for TAK-385 | Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose | — |
Countries
United States
Participant flow
Recruitment details
Participants took part in the study at 1 investigative site in the United States from 02 March 2015 to 11 June 2015.
Pre-assignment details
Healthy participants were enrolled equally in 1 of 2 treatment arms each with 6 sequences that determined the order of administration of TAK-385 tablet formulations. Arm 1: T2 fasted, T4 B fasted or T4 B fed and Arm 2: T2 fasted, T4 C fasted or T4 C fed.
Participants by arm
| Arm | Count |
|---|---|
| Arm 1: T2-A + T4B-B + T4B-C T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose. | 27 |
| Arm 2: T2-A + T4C-D + T4C-E T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose. | 27 |
| Total | 54 |
Baseline characteristics
| Characteristic | Arm 2: T2-A + T4C-D + T4C-E | Arm 1: T2-A + T4B-B + T4B-C | Total |
|---|---|---|---|
| Age, Continuous | 38.8 years STANDARD_DEVIATION 10.08 | 39.0 years STANDARD_DEVIATION 11.62 | 38.9 years STANDARD_DEVIATION 10.78 |
| Body Mass Index | 27.148 kg/m^2 STANDARD_DEVIATION 3.6504 | 27.311 kg/m^2 STANDARD_DEVIATION 2.7624 | 27.230 kg/m^2 STANDARD_DEVIATION 3.2074 |
| Height | 175.4 cm STANDARD_DEVIATION 6.79 | 174.3 cm STANDARD_DEVIATION 10.1 | 174.8 cm STANDARD_DEVIATION 8.54 |
| Race/Ethnicity, Customized Asian | 1 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Black or African American | 4 participants | 4 participants | 8 participants |
| Race/Ethnicity, Customized Hispanic or Latino | 14 participants | 21 participants | 35 participants |
| Race/Ethnicity, Customized Multiple | 1 participants | 0 participants | 1 participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 13 participants | 6 participants | 19 participants |
| Race/Ethnicity, Customized White | 21 participants | 23 participants | 44 participants |
| Region of Enrollment United States | 27 participants | 27 participants | 54 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 27 Participants | 27 Participants | 54 Participants |
| Weight | 83.69 kg STANDARD_DEVIATION 13.678 | 83.07 kg STANDARD_DEVIATION 11.957 | 83.38 kg STANDARD_DEVIATION 12.729 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 1 / 27 | 2 / 27 | 2 / 27 | 1 / 27 | 1 / 27 | 2 / 27 |
| serious Total, serious adverse events | 0 / 27 | 0 / 27 | 0 / 27 | 0 / 27 | 0 / 27 | 0 / 27 |
Outcome results
Primary
AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385
Time frame: Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose
Population: PK-Evaluable population included participants who had sufficient dosing and PK data for analysis, and who did not receive any excluded medications.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm 1: T2 Formulation Fasted | AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385 | 447 ng•hr/mL | Geometric Coefficient of Variation 64.7 |
| Arm 1: T4 Formulation B Fasted | AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385 | 440 ng•hr/mL | Geometric Coefficient of Variation 83.3 |
| Arm 1: T4 Formulation B Fed | AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385 | 350 ng•hr/mL | Geometric Coefficient of Variation 65 |
| Arm 2: T2 Formulation Fasted | AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385 | 532 ng•hr/mL | Geometric Coefficient of Variation 55.4 |
| Arm 2: T4 Formulation C Fasted | AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385 | 415 ng•hr/mL | Geometric Coefficient of Variation 85.1 |
| Arm 2: T4 Formulation C Fed | AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385 | 386 ng•hr/mL | Geometric Coefficient of Variation 52.4 |
90% CI: [74.83, 119.4]
90% CI: [64.29, 94.61]
90% CI: [64.21, 102.37]
90% CI: [76.48, 112.55]
Primary
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385
Time frame: Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose
Population: PK-Evaluable population included participants who had sufficient dosing and PK data for analysis, and who did not receive any excluded medications.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm 1: T2 Formulation Fasted | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385 | 476 ng*hr/mL | Geometric Coefficient of Variation 63.5 |
| Arm 1: T4 Formulation B Fasted | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385 | 467 ng*hr/mL | Geometric Coefficient of Variation 82.8 |
| Arm 1: T4 Formulation B Fed | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385 | 372 ng*hr/mL | Geometric Coefficient of Variation 64.1 |
| Arm 2: T2 Formulation Fasted | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385 | 563 ng*hr/mL | Geometric Coefficient of Variation 55.1 |
| Arm 2: T4 Formulation C Fasted | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385 | 440 ng*hr/mL | Geometric Coefficient of Variation 84.8 |
| Arm 2: T4 Formulation C Fed | AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385 | 409 ng*hr/mL | Geometric Coefficient of Variation 51.8 |
90% CI: [74.85, 119.12]
90% CI: [64.53, 94.51]
90% CI: [64.36, 102.34]
90% CI: [76.84, 112.54]
Primary
Cmax: Maximum Observed Plasma Concentration for TAK-385
Time frame: Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose
Population: Pharmacokinetic (PK)-Evaluable population included participants who had sufficient dosing and PK data for analysis, and who did not receive any excluded medications.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm 1: T2 Formulation Fasted | Cmax: Maximum Observed Plasma Concentration for TAK-385 | 46.7 ng/mL | Geometric Coefficient of Variation 114.9 |
| Arm 1: T4 Formulation B Fasted | Cmax: Maximum Observed Plasma Concentration for TAK-385 | 42.0 ng/mL | Geometric Coefficient of Variation 153.1 |
| Arm 1: T4 Formulation B Fed | Cmax: Maximum Observed Plasma Concentration for TAK-385 | 33.0 ng/mL | Geometric Coefficient of Variation 115.5 |
| Arm 2: T2 Formulation Fasted | Cmax: Maximum Observed Plasma Concentration for TAK-385 | 52.0 ng/mL | Geometric Coefficient of Variation 93.3 |
| Arm 2: T4 Formulation C Fasted | Cmax: Maximum Observed Plasma Concentration for TAK-385 | 43.5 ng/mL | Geometric Coefficient of Variation 146.8 |
| Arm 2: T4 Formulation C Fed | Cmax: Maximum Observed Plasma Concentration for TAK-385 | 41.2 ng/mL | Geometric Coefficient of Variation 105.9 |
90% CI: [58.56, 129.52]
90% CI: [59.95, 115.18]
90% CI: [52.88, 116.79]
90% CI: [67.98, 130.61]
Secondary
Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant
Participants with shifts from normal at Baseline in safety laboratory values (Clinical Chemistry, Hematology and Urinalysis) collected throughout study. Low=below normal reference range, Normal=within reference range, High=above normal reference range and Abnormal=outside of normal reference range.
Time frame: Baseline and Days 4, 10, 14, 20, 24 and 26
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Basophils_Normal to High | 3 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Occult blood_Normal to Abnormal | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Neutrophils_Normal to Low | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Chloride_Normal to Low | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Sodium_Normal to High | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute neutrophils_Normal to Low | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Aspartate aminotransferase (AST)_Normal to Low | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute Monocytes_Normal to High | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Creatinine_Normal to High | 0 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Monocytes_Normal to High | 0 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to Low | 1 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to High | 1 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Specific gravity_Normal to Abnormal | 2 participants |
| Arm 1: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Lymphocytes_Normal to High | 2 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Lymphocytes_Normal to High | 1 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Basophils_Normal to High | 3 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to High | 0 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Occult blood_Normal to Abnormal | 0 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Chloride_Normal to Low | 1 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Aspartate aminotransferase (AST)_Normal to Low | 1 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute neutrophils_Normal to Low | 2 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Creatinine_Normal to High | 0 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Specific gravity_Normal to Abnormal | 0 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Neutrophils_Normal to Low | 2 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute Monocytes_Normal to High | 2 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Sodium_Normal to High | 2 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Monocytes_Normal to High | 0 participants |
| Arm 1: T4 Formulation B Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to Low | 2 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Sodium_Normal to High | 1 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Aspartate aminotransferase (AST)_Normal to Low | 3 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Chloride_Normal to Low | 2 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Creatinine_Normal to High | 0 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to Low | 1 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to High | 0 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Basophils_Normal to High | 3 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Lymphocytes_Normal to High | 0 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Monocytes_Normal to High | 3 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute Monocytes_Normal to High | 1 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Neutrophils_Normal to Low | 0 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute neutrophils_Normal to Low | 0 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Occult blood_Normal to Abnormal | 0 participants |
| Arm 1: T4 Formulation B Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Specific gravity_Normal to Abnormal | 2 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Aspartate aminotransferase (AST)_Normal to Low | 1 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute Monocytes_Normal to High | 0 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to High | 0 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Specific gravity_Normal to Abnormal | 0 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Occult blood_Normal to Abnormal | 0 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Creatinine_Normal to High | 0 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Neutrophils_Normal to Low | 1 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Basophils_Normal to High | 1 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Lymphocytes_Normal to High | 1 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Monocytes_Normal to High | 0 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to Low | 0 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Chloride_Normal to Low | 3 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Sodium_Normal to High | 3 participants |
| Arm 2: T2 Formulation Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute neutrophils_Normal to Low | 1 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to Low | 0 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Lymphocytes_Normal to High | 1 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Sodium_Normal to High | 1 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Aspartate aminotransferase (AST)_Normal to Low | 3 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Monocytes_Normal to High | 1 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute Monocytes_Normal to High | 0 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Creatinine_Normal to High | 0 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Neutrophils_Normal to Low | 1 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Chloride_Normal to Low | 0 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute neutrophils_Normal to Low | 1 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Specific gravity_Normal to Abnormal | 0 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to High | 0 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Occult blood_Normal to Abnormal | 0 participants |
| Arm 2: T4 Formulation C Fasted | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Basophils_Normal to High | 1 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to Low | 0 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute neutrophils_Normal to Low | 1 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Monocytes_Normal to High | 1 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Aspartate aminotransferase (AST)_Normal to Low | 0 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Basophils_Normal to High | 3 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Sodium_Normal to High | 2 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Occult blood_Normal to Abnormal | 0 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Specific gravity_Normal to Abnormal | 0 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Urate_Normal to High | 0 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Neutrophils_Normal to Low | 1 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Chloride_Normal to Low | 1 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Lymphocytes_Normal to High | 2 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Absolute Monocytes_Normal to High | 0 participants |
| Arm 2: T4 Formulation C Fed | Number of Participants With Shifts From Normal at Baseline in Safety Laboratory Values in More Than 1 Participant | Creatinine_Normal to High | 2 participants |
Secondary
Oral Clearance (CL/F) for TAK-385
Time frame: Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose
Population: Pharmacokinetic (PK)-Evaluable population included participants who had sufficient dosing and PK data for analysis, and who did not receive any excluded medications.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Arm 1: T2 Formulation Fasted | Oral Clearance (CL/F) for TAK-385 | 252 liters (L)/hr | Geometric Coefficient of Variation 63.6 |
| Arm 1: T4 Formulation B Fasted | Oral Clearance (CL/F) for TAK-385 | 257 liters (L)/hr | Geometric Coefficient of Variation 82.7 |
| Arm 1: T4 Formulation B Fed | Oral Clearance (CL/F) for TAK-385 | 322 liters (L)/hr | Geometric Coefficient of Variation 64 |
| Arm 2: T2 Formulation Fasted | Oral Clearance (CL/F) for TAK-385 | 213 liters (L)/hr | Geometric Coefficient of Variation 55.1 |
| Arm 2: T4 Formulation C Fasted | Oral Clearance (CL/F) for TAK-385 | 273 liters (L)/hr | Geometric Coefficient of Variation 84.8 |
| Arm 2: T4 Formulation C Fed | Oral Clearance (CL/F) for TAK-385 | 293 liters (L)/hr | Geometric Coefficient of Variation 51.9 |
Secondary
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: From Day 1 to 30 days after the last dose of study drug (Up to 51 days total)
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1: T2 Formulation Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 4 percentage of participants |
| Arm 1: T2 Formulation Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 percentage of participants |
| Arm 1: T4 Formulation B Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 percentage of participants |
| Arm 1: T4 Formulation B Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 7 percentage of participants |
| Arm 1: T4 Formulation B Fed | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 7 percentage of participants |
| Arm 1: T4 Formulation B Fed | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 percentage of participants |
| Arm 2: T2 Formulation Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 percentage of participants |
| Arm 2: T2 Formulation Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 4 percentage of participants |
| Arm 2: T4 Formulation C Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 4 percentage of participants |
| Arm 2: T4 Formulation C Fasted | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 percentage of participants |
| Arm 2: T4 Formulation C Fed | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 7 percentage of participants |
| Arm 2: T4 Formulation C Fed | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 percentage of participants |
Secondary
Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant
A 12-lead ECG was administered. The investigator interpreted the ECG using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant.
Time frame: Days 1, 11, 21 and 26
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm 1: T2 Formulation Fasted | Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant | 0 percentage of participants |
| Arm 1: T4 Formulation B Fasted | Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant | 0 percentage of participants |
| Arm 1: T4 Formulation B Fed | Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant | 0 percentage of participants |
| Arm 2: T2 Formulation Fasted | Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant | 0 percentage of participants |
| Arm 2: T4 Formulation C Fasted | Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant | 0 percentage of participants |
| Arm 2: T4 Formulation C Fed | Percentage of Participants With Electrocardiogram (ECG) Parameters Abnormal and Clinically Significant | 0 percentage of participants |
Secondary
Percentage of Participants With Markedly Abnormal Vital Sign Measurements
The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study.
Time frame: From Day 1 to Day 26
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm 1: T2 Formulation Fasted | Percentage of Participants With Markedly Abnormal Vital Sign Measurements | 0 percentage of participants |
| Arm 1: T4 Formulation B Fasted | Percentage of Participants With Markedly Abnormal Vital Sign Measurements | 0 percentage of participants |
| Arm 1: T4 Formulation B Fed | Percentage of Participants With Markedly Abnormal Vital Sign Measurements | 0 percentage of participants |
| Arm 2: T2 Formulation Fasted | Percentage of Participants With Markedly Abnormal Vital Sign Measurements | 0 percentage of participants |
| Arm 2: T4 Formulation C Fasted | Percentage of Participants With Markedly Abnormal Vital Sign Measurements | 0 percentage of participants |
| Arm 2: T4 Formulation C Fed | Percentage of Participants With Markedly Abnormal Vital Sign Measurements | 0 percentage of participants |
Secondary
Terminal Phase Elimination Half-Life (T1/2) for TAK-385
Time frame: Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose
Population: Pharmacokinetic (PK)-Evaluable population included participants who had sufficient dosing and PK data for analysis, and who did not receive any excluded medications.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Arm 1: T2 Formulation Fasted | Terminal Phase Elimination Half-Life (T1/2) for TAK-385 | 36.3 hours | Standard Deviation 4.4 |
| Arm 1: T4 Formulation B Fasted | Terminal Phase Elimination Half-Life (T1/2) for TAK-385 | 36.1 hours | Standard Deviation 4.9 |
| Arm 1: T4 Formulation B Fed | Terminal Phase Elimination Half-Life (T1/2) for TAK-385 | 35.1 hours | Standard Deviation 4.11 |
| Arm 2: T2 Formulation Fasted | Terminal Phase Elimination Half-Life (T1/2) for TAK-385 | 34.9 hours | Standard Deviation 4.13 |
| Arm 2: T4 Formulation C Fasted | Terminal Phase Elimination Half-Life (T1/2) for TAK-385 | 35.5 hours | Standard Deviation 4.22 |
| Arm 2: T4 Formulation C Fed | Terminal Phase Elimination Half-Life (T1/2) for TAK-385 | 35.4 hours | Standard Deviation 2.97 |
Secondary
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385
Time frame: Days 1, 11, and 21 predose and at multiple time points (up to 120 hours) post-dose
Population: Pharmacokinetic (PK)-Evaluable population included participants who had sufficient dosing and PK data for analysis, and who did not receive any excluded medications.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm 1: T2 Formulation Fasted | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 | 2.01 hours |
| Arm 1: T4 Formulation B Fasted | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 | 3.00 hours |
| Arm 1: T4 Formulation B Fed | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 | 3.00 hours |
| Arm 2: T2 Formulation Fasted | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 | 3.00 hours |
| Arm 2: T4 Formulation C Fasted | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 | 3.00 hours |
| Arm 2: T4 Formulation C Fed | Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385 | 3.00 hours |